If your feed is full of men telling you that low testosterone is secretly ruining your energy, your sex drive, and your ambition, you are seeing a marketing engine, not a medical consensus. A recent CNN report, "Inside the testosterone boom dominating your algorithm," documents how "low T" became one of the most profitable narratives in the manosphere, and a peer-reviewed analysis found that the overwhelming majority of this content is produced by accounts with a financial stake in selling you something. Real low testosterone exists and is treatable, but separating it from the hype is the whole game.
What is actually driving the "low T" boom?
The short answer is that a real medical condition became a highly monetizable content category. Testosterone prescribing has climbed sharply in recent years, and much of the demand is being manufactured upstream, on the platforms where men spend their time.
CNN's reporting traces the boom to "manosphere" influencers on TikTok, Instagram, and YouTube, where hypermasculine fitness personalities frame testosterone as a master key to male success, tied not just to muscle but to confidence, wealth, productivity, and sexual dominance (CNN, 2026). The framing works because it attaches a simple chemical explanation, and a simple product, to a broad set of anxieties men already have.
The prescribing data reflects the pressure. Testosterone prescriptions in the UK rose 135 percent between 2021 and 2024 (News-Medical, 2026).
How much of this content is actually selling something?
Most of it. A 2026 study published in Social Science & Medicine, titled "Selling masculinity," analyzed 200 posts about low testosterone, 100 from Instagram and 100 from TikTok. The findings are stark: 72 percent of the accounts had a financial interest, such as a wellness brand or pharmaceutical sponsorship, and 67 percent of posts included commercial links to clinic consultations. Roughly a third of the accounts were ostensibly owned by medical doctors, which lends the content an air of authority (News-Medical, 2026).
The most important finding is the simplest one: none of the analyzed posts provided evidence to support their claims. The content is persuasion, not information. In the United States, social media promotion of this kind has been associated with more than $400 million in testosterone therapy sales.
This does not mean testosterone therapy is a scam. It means the funnel that delivers most men to it is built to convert, not to diagnose.
What real low testosterone looks like
Clinically, low testosterone (hypogonadism) is not a vibe or a feeling of being off your peak. It is a specific condition defined by consistently low blood testosterone levels together with symptoms, confirmed by testing, not by a quiz on a landing page.
Diagnosis requires a blood test, ideally drawn in the morning when testosterone peaks, and typically repeated on a second day to confirm, because a single low reading can be caused by illness, poor sleep, or normal fluctuation. A legitimate workup also looks for why levels are low, since obesity, thyroid problems, sleep apnea, and certain medications can all suppress testosterone, and some of those are more directly treatable than the low T itself.
The symptoms that genuinely track with low testosterone (persistent low libido, erectile difficulty, fatigue, loss of muscle, depressed mood) overlap heavily with dozens of other conditions. That overlap is exactly what makes the online funnel effective: almost every man can find himself in the symptom list. The clinical question is whether your testosterone is actually low and whether it is the cause, and that question can only be answered with lab work and a real evaluation.
Why the overdiagnosis concern is real
The study authors and the clinicians CNN interviewed share a specific worry: healthy men with normal testosterone being diagnosed and treated anyway. This matters because testosterone therapy is not risk-free. The documented risks associated with TRT include cardiovascular issues, male infertility, acute kidney injury, pulmonary embolism, loss of libido, and erectile dysfunction (News-Medical, 2026).
Infertility deserves particular emphasis for younger men, because it is the risk most often glossed over in promotional content. Exogenous testosterone suppresses the body's own production and can impair sperm production, sometimes durably. A man who wants children and is sold TRT as a lifestyle upgrade may not be told this clearly.
The point is not that TRT is dangerous for everyone. For men with genuine, confirmed hypogonadism, it is a well-established treatment with real benefits. The point is that the risk-benefit math only works when the diagnosis is real, and the online boom is optimized to skip that step.
